Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 26


Neo-adjuvant hormone therapy for non-metastatic prostate cancer: a systematic review and meta-analysis of 5,194 patients.

Hu J, Xu H, Zhu W, Wu F, Wang J, Ding Q, Jiang H.

World J Surg Oncol. 2015 Feb 22;13:73. doi: 10.1186/s12957-015-0503-z.


Current status of radical prostatectomy for high-risk prostate cancer.

Kang HW, Lee JY, Kwon JK, Jeh SU, Jung HD, Choi YD.

Korean J Urol. 2014 Oct;55(10):629-35. doi: 10.4111/kju.2014.55.10.629. Epub 2014 Oct 10. Review.


Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity.

Henríquez I, Sancho G, Hervás A, Guix B, Pera J, Gutierrez C, Abuchaibe O, Martínez-Monge R, Tormo A, Polo A.

Radiat Oncol. 2014 Apr 30;9:102. doi: 10.1186/1748-717X-9-102.


Generation of "virtual" control groups for single arm prostate cancer adjuvant trials.

Jia Z, Lilly MB, Koziol JA, Chen X, Xia XQ, Wang Y, Skarecky D, Sutton M, Sawyers A, Ruckle H, Carpenter PM, Wang-Rodriguez J, Jiang J, Deng M, Pan C, Zhu JG, McLaren CE, Gurley MJ, Lee C, McClelland M, Ahlering T, Kattan MW, Mercola D.

PLoS One. 2014 Jan 21;9(1):e85010. doi: 10.1371/journal.pone.0085010. eCollection 2014.


Analysis of prognostic factors in localized high-risk prostate cancer patients treated with HDR brachytherapy, hypofractionated 3D-CRT and neoadjuvant/adjuvant androgen deprivation therapy (trimodality therapy).

Aoki M, Miki K, Kido M, Sasaki H, Nakamura W, Kijima Y, Kobayashi M, Egawa S, Kanehira C.

J Radiat Res. 2014 May;55(3):527-32. doi: 10.1093/jrr/rrt134. Epub 2013 Dec 17.


Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials.

Schweizer MT, Huang P, Kattan MW, Kibel AS, de Wit R, Sternberg CN, Epstein JI, Eisenberger MA.

Cancer. 2013 Oct 15;119(20):3610-8. doi: 10.1002/cncr.28270. Epub 2013 Aug 13.


Significance of neoadjuvant hormonal therapy in radical retropubic prostatectomy: a retrospective single-surgeon study.

Yamamichi F, Shigemura K, Morishita S, Yamanaka K, Tanaka K, Miyake H, Fujisawa M.

Yonsei Med J. 2013 Mar 1;54(2):410-5. doi: 10.3349/ymj.2013.54.2.410.


Treatment of locally advanced prostate cancer: a case report and narrative review.

Peinemann F, Pinkawa M.

Case Rep Urol. 2012;2012:402513. doi: 10.1155/2012/402513. Epub 2012 Dec 17.


Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?

Bourke L, Kirkbride P, Hooper R, Rosario AJ, Chico TJ, Rosario DJ.

Br J Cancer. 2013 Jan 15;108(1):9-13. doi: 10.1038/bjc.2012.523. Epub 2012 Nov 29. Review.


Contemporary radical prostatectomy.

Fu Q, Moul JW, Sun L.

Prostate Cancer. 2011;2011:645030. doi: 10.1155/2011/645030. Epub 2011 Apr 14.


Management of high-risk localized prostate cancer.

Marciscano AE, Hardee ME, Sanfilippo N.

Adv Urol. 2012;2012:641689. doi: 10.1155/2012/641689. Epub 2011 Nov 1.


Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer.

Smith MR, Malkowicz SB, Brawer MK, Hancock ML, Morton RA, Steiner MS.

J Urol. 2011 Dec;186(6):2239-44. doi: 10.1016/j.juro.2011.07.090. Epub 2011 Oct 19.


Radical prostatectomy: an option for high-risk prostate cancer.

Rausch S, Schmitt C, Kälble T.

Adv Urol. 2012;2012:410246. doi: 10.1155/2012/410246. Epub 2011 Oct 11.


Health-related quality of life and cancer clinical trials.

Osoba D.

Ther Adv Med Oncol. 2011 Mar;3(2):57-71. doi: 10.1177/1758834010395342.


Risk stratification in the hormonal treatment of patients with prostate cancer.

Uhlman MA, Moul JW, Tang P, Stackhouse DA, Sun L.

Ther Adv Med Oncol. 2009 Sep;1(2):79-94. doi: 10.1177/1758834009340164.


Radical prostatectomy for high-risk clinically localized prostate cancer: a prospective single institution series.

Koupparis AJ, Grummet JP, Hurtado-Coll A, Bell RH, Buchan N, Goldenberg SL, Gleave ME.

Can Urol Assoc J. 2011 Dec;5(6):E156-61. doi: 10.5489/cuaj.10057. Epub 2011 Mar 1.


Multimodal approaches to high-risk prostate cancer.

Koupparis A, Gleave ME.

Curr Oncol. 2010 Sep;17 Suppl 2:S33-7.


Role of radical prostatectomy for high-risk prostate cancer.

You D, Jeong IG, Kim CS.

Korean J Urol. 2010 Sep;51(9):589-95. doi: 10.4111/kju.2010.51.9.589. Epub 2010 Sep 16.


Results of a randomized phase I dose-finding trial of several doses of isoflavones in men with localized prostate cancer: administration prior to radical prostatectomy.

Kumar NB, Kang L, Pow-Sang J, Xu P, Allen K, Riccardi D, Besterman-Dahan K, Krischer JP.

J Soc Integr Oncol. 2010 Winter;8(1):3-13.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk